Department of Oral and Maxillofacial Surgery, University Hospital of Oulu, Finland.
Surg Oncol. 2011 Mar;20(1):e18-22. doi: 10.1016/j.suronc.2010.08.004. Epub 2010 Sep 29.
Osteosarcoma (OS) is among most common malignant tumour of bone. Matrix metalloproteinases (MMPs) are predominantly associated with poor prognosis of several cancers, although some of them, like MMP-8, seem to have a protective role in some cancers. We analyzed the distribution patterns of MMP-2, -8, -13, -26, and tissue inhibitor of matrix metalloproteinase (TIMP)-1 in 25 OS patients. MMP-2, -8, -13, -26 and TIMP-1 were mostly detected in sarcoma cells. Response to chemotherapy affected the amount of MMP-2, -8, and -13 in resection sections when compared to biopsies: patients with excellent or good response had less positivity to MMP-2 in chemotherapy samples than those with moderate or poor response. We conclude that MMP-2, -8, -13, -26, and TIMP-1 are expressed in OS tissue, and all, except protective MMP-8, were also found in metastases indicating that MMPs and TIMP-1 can participate in the OS progression.
骨肉瘤（OS）是最常见的骨恶性肿瘤之一。基质金属蛋白酶（MMPs）主要与几种癌症的预后不良相关，尽管其中一些，如 MMP-8，在某些癌症中似乎具有保护作用。我们分析了 25 名骨肉瘤患者中 MMP-2、-8、-13、-26 和基质金属蛋白酶组织抑制剂（TIMP）-1 的分布模式。MMP-2、-8、-13、-26 和 TIMP-1 主要在肉瘤细胞中检测到。与活检相比，化疗后的反应影响了切除标本中 MMP-2、-8 和 -13 的数量：对化疗有良好或极好反应的患者与对化疗有中等或较差反应的患者相比，在化疗样本中 MMP-2 的阳性率较低。我们得出结论，MMP-2、-8、-13、-26 和 TIMP-1 在骨肉瘤组织中表达，除了具有保护作用的 MMP-8 外，所有这些都在转移灶中也有发现，这表明 MMPs 和 TIMP-1 可以参与骨肉瘤的进展。
